Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIα and Akt pathway inhibitor, and evaluation of its anti-melanoma activity
作者:Deepkamal N. Karelia、Ugir Hossain Sk、Parvesh Singh、A.S. Prakasha Gowda、Manoj K. Pandey、Srinivasa R. Ramisetti、Shantu Amin、Arun K. Sharma
DOI:10.1016/j.ejmech.2017.04.052
日期:2017.7
Synthesis and anti-melanoma activity of novel naphthalimide isoselenocyanate (NISC) and naphthalimide selenourea (NSU) analogs are described. The novel agents were screened for growth inhibition of different human melanoma cell lines including those having BRAFV600E mutation (UACC903, 1205Lu, and A375M) and BRAFWT (CHL-1). In general, the NISC analogs (4a-d) were more effective in inhibiting the cell
描述了新型萘二甲酰亚胺异异氰酸酯(NISC)和萘二甲酰亚胺硒(NSU)类似物的合成及其抗黑素瘤活性。筛选了新试剂对不同人类黑素瘤细胞系的生长抑制作用,包括具有BRAFV600E突变(UACC903、1205Lu和A375M)和BRAFWT(CHL-1)的那些。通常,NISC类似物(4a-d)比NSU类似物(7a-b)更有效地抑制细胞活力。总体而言,具有六碳烷基链的NISC-6(4d)被认为是BRAFV600E突变和BRAFWT细胞中最具细胞毒性的化合物。NISC-6与Akt1和人类拓扑异构酶IIα(Topo-IIα)的结合位点强烈对接,对接结果得到实验结果的支持,表明NISC-6以剂量依赖性方式抑制Akt途径和Topo-IIα活性。此外,